Nebenwirkungen · Myclausen
Myclausen 500 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 13
HOS-212936 · Präparat HOS-155006
Malignancies Patients receiving immunosuppressive regimens involving combinations of medicinal products, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.4). Three-year safety data in renal and cardiac transplant patients did not reveal any unexpected changes in incidence of malignancy compared to the 1-year data. Hepatic transplant patients were followed for at least 1 year, but less than 3 years.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T14:45:00Z · SHA-256 5212e91cac7f54413fc4524ec82e254c35610b87ec825a71d5d295c67a8c8df9 · Passage cfbd7ff22f703ec70c51630dc6f79438e99977d3a3826658d819d24f5d1626a2 · Zeichen 12621–13116 im Abschnitt